FOR IMMEDIATE RELEASE
Media Contact:
Katrina Norfleet
+1.240.221.2924
knorfleet@arvo.org
Posted: 5/8/2017
One in five patients in eye clinics have depression, study suggests
 

Baltimore, Md. – A survey of adult participants seen in an urban eye hospital revealed that one-in-five study participants had clinically significant depressive symptoms. The research is being presented at the 2017 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO) this week in Baltimore, Md.
Depression was found to be strongly associated with three risk factors: low vision, smoking and diabetes.

According to the researchers, few ophthalmologists currently discuss depression with patients and may be unaware of the impact that depression can have on patients’ eye health, including not taking their medication and reduced activity level. The researchers recommended that eye care patients with the associated risk factors be routinely screened for depression by taking the five-minute, PHQ-9 survey used in the study.
Abstract title: Prevalence and risk factors of depressive disorders in an urban, ophthalmic population Presentation start/end time: Monday, May 8, 2017, 8:30 – 10:15am Location: Exhibit/Poster Hall Abstract number: 1342 - A0311.

# # #

The Association for Research in Vision and Ophthalmology (ARVO) is the largest eye and vision research organization in the world. Members include nearly 12,000 eye and vision researchers from over 75 countries. ARVO advances research worldwide into understanding the visual system and preventing, treating and curing its disorders.

All abstracts accepted for presentation at the ARVO Annual Meeting represent previously unpublished data and conclusions. This research may be proprietary or may have been submitted for journal publication. Embargo policy: Journalists must seek approval from the presenter(s) before reporting data from paper or poster presentations. Press releases or stories on information presented at the ARVO Annual Meeting may not be released or published until the conclusion of the presentation.

Advertisement
Iris-may31